Effects of Paclitaxel on Plasma Membrane Microviscosity and Lipid Composition in Cancer Cells.

FLIM microscopy cancer cells mass spectrometry ToF-SIMS microviscosity molecular rotor paclitaxel plasma membrane

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
29 Jul 2023
Historique:
received: 30 06 2023
revised: 22 07 2023
accepted: 26 07 2023
medline: 14 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

The cell membrane is an important regulator for the cytotoxicity of chemotherapeutic agents. However, the biochemical and biophysical effects that occur in the membrane under the action of chemotherapy drugs are not fully described. In the present study, changes in the microviscosity of membranes of living HeLa-Kyoto tumor cells were studied during chemotherapy with paclitaxel, a widely used antimicrotubule agent. To visualize the microviscosity of the membranes, fluorescence lifetime imaging microscopy (FLIM) with a BODIPY 2 fluorescent molecular rotor was used. The lipid profile of the membranes was assessed using time-of-flight secondary ion mass spectrometry ToF-SIMS. A significant, steady-state decrease in the microviscosity of membranes, both in cell monolayers and in tumor spheroids, was revealed after the treatment. Mass spectrometry showed an increase in the unsaturated fatty acid content in treated cell membranes, which may explain, at least partially, their low microviscosity. These results indicate the involvement of membrane microviscosity in the response of tumor cells to paclitaxel treatment.

Identifiants

pubmed: 37569560
pii: ijms241512186
doi: 10.3390/ijms241512186
pmc: PMC10419023
pii:
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Russian Science Foundation
ID : 20-14-00111

Références

J Biomed Mater Res. 1999 Aug;46(2):141-9
pubmed: 10379991
Int J Pharm. 2020 Apr 30;580:119222
pubmed: 32194209
Mol Membr Biol. 2000 Apr-Jun;17(2):95-100
pubmed: 10989459
Cancers (Basel). 2021 Dec 07;13(24):
pubmed: 34944789
J Colloid Interface Sci. 2005 May 1;285(1):326-35
pubmed: 15797430
Lipids. 2008 Jun;43(6):569-79
pubmed: 18458975
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1686-98
pubmed: 24055719
J Phys Chem B. 2014 Oct 16;118(41):11965-72
pubmed: 25243601
Chem Biol Drug Des. 2012 Dec;80(6):992-1002
pubmed: 23006796
Sci Rep. 2015 Apr 17;5:9529
pubmed: 25886093
Methods Appl Fluoresc. 2022 Aug 25;10(4):
pubmed: 35970177
Adv Exp Med Biol. 2017;1035:143-153
pubmed: 29080136
Oncoscience. 2015 Jun 12;2(6):585-95
pubmed: 26244166
Proc Natl Acad Sci U S A. 1977 Mar;74(3):1072-6
pubmed: 265552
Eur J Cancer Prev. 2005 Jun;14(3):263-70
pubmed: 15901996
Biomed Pharmacother. 2019 Jun;114:108800
pubmed: 30921705
J Cell Biol. 1985 May;100(5):1357-62
pubmed: 3988793
Mol Pharm. 2010 Dec 6;7(6):2334-48
pubmed: 20958074
Front Oncol. 2014 Mar 06;4:40
pubmed: 24639951
Cell Rep. 2019 Nov 19;29(8):2371-2383.e5
pubmed: 31747606
Oxid Med Cell Longev. 2021 Oct 18;2021:3687700
pubmed: 34707776
Biochim Biophys Acta. 2009 Jul;1788(7):1415-33
pubmed: 19328773
Biophys J. 2007 Dec 15;93(12):4225-36
pubmed: 17766354
J Membr Biol. 2022 Jun;255(2-3):277-291
pubmed: 35175383
Sci Rep. 2017 Jan 30;7:41097
pubmed: 28134273
Colloids Surf B Biointerfaces. 2021 Sep;205:111889
pubmed: 34098365
Front Cell Dev Biol. 2020 Sep 02;8:571237
pubmed: 32984352
J Biomed Opt. 2020 Dec;25(12):
pubmed: 33331150
J Am Coll Nutr. 2011 Aug;30(4):265-73
pubmed: 21917707
Mol Biol Cell. 1999 Apr;10(4):947-59
pubmed: 10198049
OMICS. 2011 Oct;15(10):655-64
pubmed: 21978394
J Pharm Sci. 2004 Jan;93(1):86-98
pubmed: 14648639
Chem Commun (Camb). 2014 May 25;50(40):5282-4
pubmed: 24266030
Anticancer Res. 2020 May;40(5):2573-2582
pubmed: 32366402
Biophys J. 2009 Feb;96(3):818-30
pubmed: 19186123
Int J Pharm. 2007 Jun 29;338(1-2):258-66
pubmed: 17337138

Auteurs

Liubov Shimolina (L)

Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Minin and Pozharsky Square, 10/1, 603005 Nizhny Novgorod, Russia.

Alexander Gulin (A)

N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Kosygin st. 4, 119991 Moscow, Russia.

Alexandra Khlynova (A)

Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Minin and Pozharsky Square, 10/1, 603005 Nizhny Novgorod, Russia.

Nadezhda Ignatova (N)

Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Minin and Pozharsky Square, 10/1, 603005 Nizhny Novgorod, Russia.

Irina Druzhkova (I)

Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Minin and Pozharsky Square, 10/1, 603005 Nizhny Novgorod, Russia.

Margarita Gubina (M)

N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Kosygin st. 4, 119991 Moscow, Russia.

Elena Zagaynova (E)

Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine, Federal Medical Biological Agency, Malaya Pirogovskaya, 1a, 119435 Moscow, Russia.

Marina K Kuimova (MK)

Department of Chemistry, Imperial College London (White City Campus), London W12 0BZ, UK.

Marina Shirmanova (M)

Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Minin and Pozharsky Square, 10/1, 603005 Nizhny Novgorod, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH